Hospital Universitari Germans Trias i Pujol -ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2021

  1. Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer

    European Journal of Cancer, Vol. 148, pp. 134-145

  2. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

  3. The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

    npj Breast Cancer, Vol. 7, Núm. 1

2018

  1. Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

    Melanoma Research, Vol. 28, Núm. 3, pp. 195-203

2017

  1. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

    Oncogene, Vol. 36, Núm. 19, pp. 2737-2749

2015

  1. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors

    Melanoma Research, Vol. 25, Núm. 6, pp. 486-495

  2. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

    Nature Genetics, Vol. 47, Núm. 3, pp. 250-256

2010

  1. Editorial: Whither thou goest pain?

    Revista de la Sociedad Espanola del Dolor, Vol. 17, Núm. 4, pp. 187-189